CN107281244A - Echinacea Purpurea Herb P.E is preparing the application in preventing and treating senile dementia medicine - Google Patents
Echinacea Purpurea Herb P.E is preparing the application in preventing and treating senile dementia medicine Download PDFInfo
- Publication number
- CN107281244A CN107281244A CN201610190175.2A CN201610190175A CN107281244A CN 107281244 A CN107281244 A CN 107281244A CN 201610190175 A CN201610190175 A CN 201610190175A CN 107281244 A CN107281244 A CN 107281244A
- Authority
- CN
- China
- Prior art keywords
- echinacea
- echinacea purpurea
- purpurea herb
- herb
- dementia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000014134 echinacea Nutrition 0.000 title claims abstract description 82
- 240000004530 Echinacea purpurea Species 0.000 title claims abstract description 60
- 208000024827 Alzheimer disease Diseases 0.000 title claims abstract description 42
- 239000003814 drug Substances 0.000 title claims abstract description 31
- 206010039966 Senile dementia Diseases 0.000 title claims abstract description 21
- 244000133098 Echinacea angustifolia Species 0.000 claims abstract description 24
- 238000002360 preparation method Methods 0.000 claims abstract description 12
- 201000004810 Vascular dementia Diseases 0.000 claims abstract description 10
- 206010012289 Dementia Diseases 0.000 claims abstract description 9
- 239000000284 extract Substances 0.000 claims abstract description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 39
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 15
- 239000000463 material Substances 0.000 claims description 11
- 239000011347 resin Substances 0.000 claims description 11
- 229920005989 resin Polymers 0.000 claims description 11
- 239000000843 powder Substances 0.000 claims description 10
- 230000036541 health Effects 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 8
- 238000000605 extraction Methods 0.000 claims description 7
- 239000000706 filtrate Substances 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 6
- 239000000243 solution Substances 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 239000000047 product Substances 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 238000003810 ethyl acetate extraction Methods 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 3
- 239000008367 deionised water Substances 0.000 claims description 3
- 229910021641 deionized water Inorganic materials 0.000 claims description 3
- 239000003480 eluent Substances 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- 238000007654 immersion Methods 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 238000000746 purification Methods 0.000 claims description 3
- 238000000967 suction filtration Methods 0.000 claims description 3
- 238000010828 elution Methods 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 238000001179 sorption measurement Methods 0.000 claims description 2
- 241001579678 Panthea coenobita Species 0.000 claims 1
- 235000015091 medicinal tea Nutrition 0.000 claims 1
- 239000006188 syrup Substances 0.000 claims 1
- 235000020357 syrup Nutrition 0.000 claims 1
- 229940098465 tincture Drugs 0.000 claims 1
- 238000010175 APPswe/PSEN1dE9 Methods 0.000 abstract description 15
- 241000699670 Mus sp. Species 0.000 abstract description 9
- YDDGKXBLOXEEMN-UHFFFAOYSA-N Di-E-caffeoyl-meso-tartaric acid Natural products C=1C=C(O)C(O)=CC=1C=CC(=O)OC(C(O)=O)C(C(=O)O)OC(=O)C=CC1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-UHFFFAOYSA-N 0.000 abstract description 7
- YDDGKXBLOXEEMN-IABMMNSOSA-N chicoric acid Chemical compound O([C@@H](C(=O)O)[C@@H](OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)\C=C\C1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-IABMMNSOSA-N 0.000 abstract description 7
- 235000006193 cichoric acid Nutrition 0.000 abstract description 7
- 229930016920 cichoric acid Natural products 0.000 abstract description 7
- YDDGKXBLOXEEMN-WOJBJXKFSA-N dicaffeoyl-L-tartaric acid Natural products O([C@@H](C(=O)O)[C@@H](OC(=O)C=CC=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)C=CC1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-WOJBJXKFSA-N 0.000 abstract description 7
- 230000015654 memory Effects 0.000 abstract description 5
- 150000002989 phenols Chemical class 0.000 abstract description 4
- 230000009261 transgenic effect Effects 0.000 abstract description 4
- 230000004083 survival effect Effects 0.000 abstract 1
- 210000001320 hippocampus Anatomy 0.000 description 13
- ZQPQGKQTIZYFEF-WCVJEAGWSA-N Huperzine Natural products C1([C@H]2[C@H](O)C(=O)N[C@H]2[C@@H](O)C=2C=CC=CC=2)=CC=CC=C1 ZQPQGKQTIZYFEF-WCVJEAGWSA-N 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 238000011830 transgenic mouse model Methods 0.000 description 11
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 6
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical class OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 6
- 101150060184 ACHE gene Proteins 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 238000012347 Morris Water Maze Methods 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 102100033639 Acetylcholinesterase Human genes 0.000 description 3
- 108010022752 Acetylcholinesterase Proteins 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 210000005013 brain tissue Anatomy 0.000 description 3
- 230000001713 cholinergic effect Effects 0.000 description 3
- 230000019771 cognition Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 208000037259 Amyloid Plaque Diseases 0.000 description 2
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 2
- -1 Cichoric acid Chemical class 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 229940022698 acetylcholinesterase Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- HPOIPOPJGBKXIR-UHFFFAOYSA-N 3,6-dimethoxy-10-methyl-galantham-1-ene Natural products O1C(C(=CC=2)OC)=C3C=2CN(C)CCC23C1CC(OC)C=C2 HPOIPOPJGBKXIR-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- 241000131317 Capitulum Species 0.000 description 1
- LPCKPBWOSNVCEL-UHFFFAOYSA-N Chlidanthine Natural products O1C(C(=CC=2)O)=C3C=2CN(C)CCC23C1CC(OC)C=C2 LPCKPBWOSNVCEL-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- YDDUMTOHNYZQPO-RVXRWRFUSA-N Cynarine Chemical compound O([C@@H]1C[C@@](C[C@H]([C@@H]1O)O)(OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)\C=C\C1=CC=C(O)C(O)=C1 YDDUMTOHNYZQPO-RVXRWRFUSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 229940123511 Excitatory amino acid receptor antagonist Drugs 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- ZRJBHWIHUMBLCN-SEQYCRGISA-N Huperzine A Natural products N1C(=O)C=CC2=C1C[C@H]1/C(=C/C)[C@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-SEQYCRGISA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 1
- ZRJBHWIHUMBLCN-UHFFFAOYSA-N Shuangyiping Natural products N1C(=O)C=CC2=C1CC1C(=CC)C2(N)CC(C)=C1 ZRJBHWIHUMBLCN-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003627 anti-cholesterol Effects 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940039856 aricept Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000004456 color vision Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 229950009125 cynarine Drugs 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 235000020694 echinacea extract Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000004503 fine granule Substances 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229960003980 galantamine Drugs 0.000 description 1
- BGLNUNCBNALFOZ-WMLDXEAASA-N galanthamine Natural products COc1ccc2CCCC[C@@]34C=CCC[C@@H]3Oc1c24 BGLNUNCBNALFOZ-WMLDXEAASA-N 0.000 description 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- ZRJBHWIHUMBLCN-YQEJDHNASA-N huperzine A Chemical compound N1C(=O)C=CC2=C1C[C@H]1\C(=C/C)[C@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-YQEJDHNASA-N 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- IYVSXSLYJLAZAT-NOLJZWGESA-N lycoramine Natural products CN1CC[C@@]23CC[C@H](O)C[C@@H]2Oc4cccc(C1)c34 IYVSXSLYJLAZAT-NOLJZWGESA-N 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 1
- 229960004640 memantine Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 208000027061 mild cognitive impairment Diseases 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- ZRJBHWIHUMBLCN-BMIGLBTASA-N rac-huperzine A Natural products N1C(=O)C=CC2=C1C[C@@H]1C(=CC)[C@@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-BMIGLBTASA-N 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229960004136 rivastigmine Drugs 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 230000006886 spatial memory Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000007939 sustained release tablet Substances 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to the preparation of Echinacea Purpurea Herb P.E and application, it is characterized in that application of the Echinacea Purpurea Herb P.E in preparation prevents and treats senile dementia medicine, wherein Echinacea Purpurea Herb P.E is mainly made up of Phenolic Compounds and Cichoric acid, content both it is no less than 60%.Through experimental studies have found that, Echinacea active principle can protect the damage of 25 35 pairs of SH SY5Y cells of A β, increase the survival of SH SY5Y cells, can improve APP/PS1 double transgenic dementia mice ability of learning and memory.The Mixed dementia that the extract can be used for preventing and treating Alzheimer disease, vascular dementia, Alzheimer disease and vascular dementia and deposit is one or more of.
Description
Technical field
The present invention relates to Echinacea Purpurea Herb P.E preparation method and purposes, more particularly to Echinacea Purpurea Herb P.E is preparing the application in preventing and treating the medicine or health products of senile dementia, is belonging to field of medicaments category.
Background technology
Increasingly serious with world population ages, many diseases such as senile dementia relevant with aging etc. seriously threatens the healthy factor of the elderly as today's society, and the incidence of disease of senile dementia is in continuous ascendant trend.Senile dementia mainly includes Alzheimer disease (AD) and vascular dementia (VD), and Alzheimer disease accounts for 60~70%, and vascular dementia accounts for 20~30%.
Alzheimer disease（Alzheimer ’s disease, AD）It is a kind of degenerative disease of the central nervous system based on progressive dementia.Its Clinical symptoms is memory and other cognition dysfunctions, and early clinic symptom includes motion, felt or coordination function defect.The main pathological change of AD patient is that the missing, inflammation, oxidation of extracellular amyloid albumen precipitation formation senile plaque expelling, NFT and extensive synapse are even downright bad.
AD pathogenesis is complicated, and at present both at home and abroad still without can treat AD medicine at all, therefore early treatment is most important.The medicine listed at present is broadly divided into two kinds, and one kind is anticholinesterase, and such as Doneppezil Hydrochloride, galanthamine, rivastigmine, huperzine are first-class；Another is excitatory amino acid receptor antagonists, such as memantine.It is another to there is anti-inflammatory, anti-oxidant, anti-cholesterol, anti-beta amyloid class medicine to be used for AD auxiliary treatment.Said medicine can improve the symptom of AD patient in short term, but can not alleviate advancing of disease, and easily form resistance, and adverse reaction is obvious；And traditional Chinese medicine has preferable clinical effectiveness in preventing and treating mild cognitive impairment and senile dementia, there is multipath, the characteristics of too many levels is integrally-regulated, and it is small using the toxic side effect of natural drug.Therefore, the extraction of traditional Chinese medicine monomer or its active principle is of great significance applied to AD preventing and treating tool.
Echinacea（Echiunacea purpurea）It is composite family genus echinacea herbaceos perennial, also known as purple coneflower, gained the name because of its capitulum likeness in form pine nut, be subordinate to composite family genus echinacea, originate in America, China has introduced a fine variety drug in some provinces.Recent research result shows：Contain the materials such as a large amount of caffeic acid derivatives and alkylamide in its flower and wounded in the battle branches and leaves and root; caffeic acid derivative in Echinacea Purpurea Herb P.E has antiinflammatory action and can be by removing an oxygen species and free radical with reactivity, so as to protect skin collagen not damaged by free radical.Caffeic acid derivative includes Cichoric acid, chlorogenic acid, echinacosid, coffee tartaric acid and cinarine etc..Echinacea is mainly used as immunomodulator and immunostimulant in terms of medical science, the effects such as with antiviral, antimycotic, antitumor and desinsection, anti-inflammatory.
The main component of genus echinacea plant includes three major types, caffeic acid derivative (mainly Cichoric acid, Echinacea glycosides, two caffeic acid chinic acids etc.), alkyl amide compound and polysaccharide, additionally containing materials such as a small amount of flavones, the content of various composition is slightly different in Echinacea plant not of the same race.Contain Echinacea glucoside, polyphenol and Cichoric acid isoreactivity composition in the alcohol extract of Echinacea, have no that Echinacea active principle is used to treat the application in dementia disease medicine through retrieval.The present inventor is further study show that a kind of Echinacea Purpurea Herb P.E can significantly improve APP/PS1 double transgenic dementia mice cognition dysfunctions, and it is very great to preventing and treating senile dementia meaning.
The content of the invention
The present invention uses Echinacea, and extraction processing is carried out to it, using Echinacea Purpurea Herb P.E as main medicinal component, adds proper auxiliary materials, is prepared into the prevention and treatment of the various senile dementias such as suitable preparation Alzheimer's disease, vascular dementia.
Echinacea Purpurea Herb P.E of the present invention is prepared from according to following preparation technology, and its processing step is
（1）It by the cleaning of Echinacea medicinal material herb, dry, pulverize, cross 60~80 mesh sieves, coarse powder is made；
（2）Echinacea coarse powder is with 10~30 times of 40%~90% ethanol of amount, with 40 DEG C~70 DEG C alcohol refluxs extraction 1~3 time after immersion 20-40 minute, every time 1~3h, suction filtration, merging filtrate；
（3）Filtrate is adsorbed with macroporous resin column, is then washed with deionized water to efflux is colourless and is eluted again with 30%~70% ethanol solution；
（4）Merge the eluent after macroporous resin purification, be concentrated into the 1/10 of original volume, reclaim ethanol, adjust solution ph to be 3 with hydrochloric acid and 5%NAOH, with ethyl acetate extraction 3~4 times, collect extract, concentrated with rotary evaporator, evaporated in vacuo obtains Echinacea Purpurea Herb P.E powder at 55~65 DEG C.
Step（2）Described in the consumption of ethanol be 10~15 times of Echinacea weight, 1.5h~2h is extracted in refluxing extraction 2~3 times at 40~60 DEG C every time.
Step（2）Described in the consumption of preferred alcohol be 15 times of Echinacea weight, refluxing extraction 3 times preferably at 45 DEG C extract 2h every time.
Step（3）Described in macroreticular resin model can select AB-8, S-8, H103, NKA-9, X-5, D4020, D3520, NKA-2, D4006 etc..
Step（3）Described in the preferred AB-8 of macroreticular resin type.
Step（3）Described in ethanol elution concentration preferably 50% after macroporous resin adsorption.
Step（4）Described in after ethyl acetate extraction 4 times rotary evaporator concentrate, preferably 60 DEG C of vacuum drying temperature.
Echinacea Purpurea Herb P.E of the present invention, it is characterised in that the extract contains the composition of following percentage by weight：Phenolic Compounds 20~30%, Cichoric acid 35~60%.
Echinacea Purpurea Herb P.E of the present invention, it is characterised in that the extract contains the composition of following percentage by weight：Phenolic Compounds 22~25%, Cichoric acid 38~45%.
Echinacea Purpurea Herb P.E of the present invention can be used for preparing medicine, the health products for preventing and treating senile dementia.
Echinacea Purpurea Herb P.E of the present invention, it is characterised in that：The senile dementia is Alzheimer disease, vascular dementia, Alzheimer disease and vascular dementia and the Mixed dementia deposited is one or more of.
Echinacea Purpurea Herb P.E of the present invention, it is characterised in that：The senile dementia is mainly Alzheimer disease.
Echinacea Purpurea Herb P.E of the present invention, it is characterised in that：Using Echinacea Purpurea Herb P.E as active component, the medicament that pharmaceutically acceptable auxiliary material is made is added.
The medicine or health products of the present invention for preventing and treating senile dementia, it is characterised in that：It can be made into injection, tablet, sustained release tablets, dripping pill, granule, powder-injection, capsule, fine granule.Preferred dosage form is tablet, dripping pill, powder-injection, capsule.Can be with auxiliary material such as starch, dextrin, lactose, microcrystalline cellulose, HPMC, polyethylene glycol, magnesium stearate, superfine silica gel powder, xylitol, lactitol, glucose, glycine, mannitol, glycine etc. are mixed in any or more than one pharmacies various formulations.
It is of the present invention, it is characterised in that：Preparation can be the oral, form of non-bowel, rectum, intranasal administration, and the form of the administrations such as aerosol, inhalant can also be made.
The Echinacea Purpurea Herb P.E that the present invention is provided can be also used for preparing food supplement and/or health food, the various formulations of health food can be prepared into, such as tablet, capsule, oral liquid, health drink, health protection tea；Can also be as food additives, applied to food（Such as bread, noodles）, health protection tea, health drink etc..
Embodiment
The invention is further described below by specific embodiment.
Embodiment 1 ：The preparation technology of Echinacea Purpurea Herb P.E
It by the cleaning of Echinacea medicinal material herb, dry, pulverize, cross 80 mesh sieves, coarse powder is made；Echinacea coarse powder is extracted 3 times with 15 times of 45% ethanol of amount, immersion after 30 minutes with 45 DEG C of alcohol refluxs, each 2h, suction filtration, merging filtrate；Filtrate is adsorbed with AB-8 macroporous resin columns, is then washed with deionized water to efflux is colourless and is eluted again with 50% ethanol solution；Merge the eluent after macroporous resin purification, be concentrated into the 1/10 of original volume, reclaim ethanol, adjust solution ph to be 3 with hydrochloric acid and 5%NAOH, with ethyl acetate extraction 4 times, collect extract, concentrated with rotary evaporator, evaporated in vacuo obtains Echinacea Purpurea Herb P.E powder at 60 DEG C.HPLC determines its content, and Phenolic Compounds content is 24.1%, Cichoric acid 38.3%.
Embodiment 2：Have shown that Echinacea Purpurea Herb P.E has therapeutic action to APP/PS1 double transgenic dementia mices in body research
1 material
1.1 experimental animal
5 monthly age APP/PS1 bi-transgenic mices 48, male, body weight 25 ± 2g, SPF grade, identical genetic background C57BL/6J mouse 8 are normal control.
1.2 Experimental agents and reagent
Positive control medicine selects Doneppezil Hydrochloride (trade name：Aricept), 5mg/ pieces are smashed tablet using preceding, and gavage decoction 0.65mg/kgd is configured to distilled water- 1；Huperzine A capsule is configured to gavage decoction with distilled water, and compound concentration is 0.026mg/kgd- 1.Acetylcholinesterase (AChE) kit, cholinacetyltranslase (ChAT) kit, SOD active agents box, MDA contents kit, GSH content kits.Following " Chinese medical extracts of the present invention " refer to the Echinacea Purpurea Herb P.E in embodiment 1.
1.3 key instrument
DMS-2 type Morris water maze instrument automatic data collections and processing system, BH-2 type biomicroscopes, DpxView Pro type computer color vision processing systems, paraffin section device, instrument is dried in Full automatic closed tissue processor, embedding machine, pathological tissue drift, Image-Pro Plus image analysis systems, freeze at a high speed refrigerated centrifuge.
2 methods
2.1 packets and administration
By the body weight principle of correspondence, APP/PS1 bi-transgenic mices are divided into model group, the low dose group of embodiment 1 (8mg/kg/d), the middle dose group of embodiment 1 (16mg/kg/d), the high dose group (32mg/kg/d) of embodiment 1, Doneppezil Hydrochloride group (0.65mg/kg/d) and huperzine group at random（0.026mg/kg·d）, every group 8；The same monthly age C57BL/6J mouse 8 of identical genetic background are only used as Normal group.Normal group and model group give isometric distilled water gavage, and one time a day.Each group mouse stomach 8 weeks, to progress Morris water maze tests during 7 monthly age.
2.2 brain tissue samples are handled
Mouse is in after last Behavior test, and fasting 12h carries out brain tissue materials.The experiment such as pathology and immunohistochemical staining, tissue content measure is carried out to brain tissue.
2.4 statistical procedures
The data obtained is represented with mean ± standard deviation, statistical analysis is carried out using statistic software SPSS 18.0, data, which compare, between group uses one-way analysis of variance, is examined using LSD, Dunnett ' sC (during heterogeneity of variance), is that difference has significant with P ＜ 0.05.Orientation navigation experiment uses the variance analysis of Repeated Measurements during behaviouristics Morris water mazes are determined, and space exploration experiment uses one-way analysis of variance.
3 experimental results
Echinacea Purpurea Herb P.E shows that compared with blank control group, the escape latency of model group significantly extends to APP/PS1 bi-transgenic mices ability of learning and memory influence result in 3.1 Morris water maze laboratories（P ＜ 0.01）, the platform residence time substantially reduces（P ＜ 0.01）, spanning platform number of times substantially reduces（P ＜ 0.01）；Compared with model group, Echinacea Purpurea Herb P.E middle dose group（P ＜ 0.01）Escape latency is substantially reduced, Echinacea Purpurea Herb P.E high dose group（P ＜ 0.05）With huperzine group（P ＜ 0.05）Pass through target quadrant number of times to dramatically increase, the platform spanning platform number of times of Echinacea Purpurea Herb P.E high dose group and platform residence time dramatically increase（P ＜ 0.01）, illustrate that Echinacea Purpurea Herb P.E can improve learning and memory in rats ability；Compared with positive drug, the Echinacea Purpurea Herb P.E high dose group platform residence time is more than positive drug group than positive drug group leader and spanning platform number of times, illustrate that raising effect of the Echinacea Purpurea Herb P.E high dose group to learning and memory in rats ability is better than positive drug（It is shown in Table 1）.
Influence of the Echinacea Purpurea Herb P.E of table 1 to APP/PS1 bi-transgenic mice Spatial memory abilities
| Group | Quantity | Escape latency (s) | Target quadrant traversing times | The platform residence time (s) | The target quadrant residence time (s) | Spanning platform number of times |
| Blank control group | 8 | 19.3±2.1 | 4.6±0.4 | 1.2±0.1 | 12.4±1.0 | 2.1±0.4 |
| Model group | 8 | 37.3±3.8## | 3.3±0.3 | 0.5±0.1## | 9.8±0.8 | 1.2±0.3## |
| The low dose group of embodiment 1 | 8 | 35.1±4.1 | 3.7±0.3 | 0.6±0.1 | 10.6±1.1 | 1.9±0.2 |
| The middle dose group of embodiment 1 | 8 | 30.9±3.2* | 3.9±0.4 | 0.9±0.1 | 11.2±1.3 | 2.8±0.4 |
| The high dose group of embodiment 1 | 8 | 33.4±2.8 | 4.3±0.3* | 1.1±0.1** | 10.7±1.5 | 2.4±0.3** |
| Doneppezil Hydrochloride group | 8 | 32.2±4.1 | 3.9±0.4 | 0.7±0.1 | 11.9±1.4 | 1.8±0.3 |
| Huperzine group | 8 | 35.6±3.3 | 4.1±0.3* | 0.6±0.1 | 10.3±1.2 | 2.1±0.4 |
Compared with blank control group,#P ＜ 0.05,##P ＜ 0.01；Compared * P ＜ 0.05, * * P ＜ 0.05 with model group
3.2 Echinacea Purpurea Herb P.Es are to cholinacetyltranslase in APP/PS1 bi-transgenic mice hippocampus（AchE）And acetylcholinesterase（ChAT）The influence result of activity is shown, is compared with blank control group, and the Ach contents of model group are significantly reduced, AchE activity is dramatically increased, ChAT activity is substantially reduced；Compared with model group, Echinacea Purpurea Herb P.E middle dose group（P ＜ 0.01）, high dose group（P ＜ 0.05）With positive drug Doneppezil Hydrochloride group（P ＜ 0.01）, huperzine group（P ＜ 0.05）Ach contents dramatically increase, Echinacea Purpurea Herb P.E high dose group（P ＜ 0.05）With positive drug huperzine group（P ＜ 0.05）AchE activity substantially reduce, Echinacea Purpurea Herb P.E middle dose group（P ＜ 0.05）, high dose group（P ＜ 0.05）With positive drug Doneppezil Hydrochloride group（P ＜ 0.01）, huperzine group（P ＜ 0.05）ChAT contents dramatically increase, illustrate Echinacea Purpurea Herb P.E can by adjust cholinergic nerve system increase hippocampus of mice acetyl choline content（It is shown in Table 2）.
Influence of the Echinacea Purpurea Herb P.E of table 2 to Ach, AchE and ChAT content in APP/PS1 bi-transgenic mice hippocampus
| Group | Dosage mg/kg | Ach（ug/ml） | AchE( U/g) | ChAT( U/g) |
| Blank control group | 155.17±12.28 | 165.31±14.22 | 45.22±5.15 | |
| Model group | 77.68±9.21## | 339.51±41.04### | 22.24±3.23## | |
| The low dose group of embodiment 1 | 8.0 | 86.34±9.65 | 277.14±30.06 | 27.54±3.67 |
| The middle dose group of embodiment 1 | 16.0 | 146.47±11.08** | 268.02±31.17 | 39.66±4.08* |
| The high dose group of embodiment 1 | 32.0 | 121.66±13.80* | 221.46±28.68* | 38.71±5.07* |
| Doneppezil Hydrochloride group | 0.65 | 138.39±12.94** | 278.04±25.33 | 42.67±5.33** |
| Huperzine group | 0.026 | 124.03±13.62* | 263.09±32.67* | 38.22±4.08* |
Compared with blank control group,##P ＜ 0.01,###P ＜ 0.001；Compared * P ＜ 0.05, * * P ＜ 0.01 with model group
3.3 Echinacea Purpurea Herb P.Es are to APP/PS1 bi-transgenic mice hippocampus person in middle and old age's spots（SP）Influence result show that compared with blank control group, SP quantity is dramatically increased in model group hippocampus of mice（P ＜ 0.001）；Compared with model group, Echinacea Purpurea Herb P.E middle dose group（P ＜ 0.01）, high dose group（P ＜ 0.05）With positive drug huperzine group（P ＜ 0.05）SP quantity is substantially reduced in hippocampus of mice, illustrates that Echinacea Purpurea Herb P.E can reduce APP/PS1 bi-transgenic mice hippocampus person in middle and old age spot deposition（It is shown in Table 3）.
The Echinacea Purpurea Herb P.E of table 3 is to APP/PS1 bi-transgenic mice hippocampus person in middle and old age's spots（SP）Influence
| Group | Dosage mg/kg | Size of animal | SP quantity（It is individual） |
| Blank control group | 8 | 1.8±0.3 | |
| Model group | 8 | 21.5±4.6### | |
| The low dose group of embodiment 1 | 8.0 | 8 | 18.1±3.4 |
| The middle dose group of embodiment 1 | 16.0 | 8 | 10.7±2.9** |
| The high dose group of embodiment 1 | 32.0 | 8 | 12.8±2.6* |
| Doneppezil Hydrochloride group | 0.65 | 8 | 14.5±2.8 |
| Huperzine group | 0.026 | 8 | 13.8±3.1* |
Compared with blank control group,###P ＜ 0.001；Compared * P ＜ 0.05, * * P ＜ 0.01 with model group
3.4 Echinacea Purpurea Herb P.Es are shown to APP/PS1 bi-transgenic mice hippocampus SOD activity, MDA contents, the result of GSH contents, are compared with blank control group, and the SOD activity of model group is substantially reduced, MDA contents are dramatically increased, GSH contents are substantially reduced；Compared with model group, Echinacea Purpurea Herb P.E middle dose group（P ＜ 0.001）, high dose group（P ＜ 0.05）With positive drug huperzine group（P ＜ 0.01）SOD activity is dramatically increased, Echinacea Purpurea Herb P.E middle dosage, high dose group and positive drug group（P ＜ 0.05）MDA contents are substantially reduced, and illustrate that Echinacea Purpurea Herb P.E can improve the oxidation resistance of Rat hippocampus（It is shown in Table 4）.
The Echinacea Purpurea Herb P.E of table 4 influences on SOD activity, MDA contents, GSH contents in APP/PS1 bi-transgenic mice hippocampus
| Group | Dosage mg/kg | SOD(U/mgprot) | MDA(nmol/mgprot) | GSH(mg/gprot) |
| Blank control group | 121.37±7.97 | 3.46±0.33 | 8.21±0.53 | |
| Model group | 55.29±4.42### | 9.27±0.94## | 5.33±0.67# | |
| The low dose group of embodiment 1 | 8.0 | 88.31±6.07 | 6.23±0.78 | 5.05±0.88 |
| The middle dose group of embodiment 1 | 16.0 | 137.05±6.20*** | 4.06±0.51* | 5.97±0.73 |
| The high dose group of embodiment 1 | 32.0 | 107.80±7.53* | 3.97±040* | 6.60±0.78 |
| Doneppezil Hydrochloride group | 0.65 | 89.66±6.32 | 3.88±0.37* | 5.80±0.87 |
| Huperzine group | 0.026 | 113.49±6.71** | 4.12±0.42* | 6.33±0.91 |
Compared with blank control group,#P ＜ 0.05,##P ＜ 0.01；Compared * P ＜ 0.05, * * P ＜ 0.01, * * * P ＜ 0.001 with model group
Echinacea Purpurea Herb P.E can improve APP/PS1 double transgenic dementia mice cognition dysfunctions；Echinacea Purpurea Herb P.E can adjust cholinergic nerve system increase hippocampus of mice acetyl choline content, reduce senile plaque expelling（SP）Occur；Echinacea Purpurea Herb P.E can improve the oxidation resistance of Hippocampus of Mice, increase SOD activity, reduction MDA contents, increase GSH contents.
The medicine that the present invention treats senile dementia using Echinacea Purpurea Herb P.E as preparing; the pharmacodynamic evaluation that Echinacea Purpurea Herb P.E prevents and treats senile dementia is carried out using related pharmacology test; respectively in terms of improving cholinergic nerve of centrum system, suppressing amyloid beta (A β) formation and deposition, neuroprotection, the purposes that Echinacea Purpurea Herb P.E multipath, Mutiple Targets treat senile dementia is illustrated.
Claims (9)
1. a kind of Echinacea Purpurea Herb P.E, its preparation method comprises the following steps：
Echinacea medicinal material herb crushed 60~80 mesh sieves, obtained Echinacea coarse powder；Echinacea coarse powder is with 10~30 times of 40%~90% ethanol of amount, with 40 DEG C~70 DEG C alcohol refluxs extraction 1~3 time after immersion 20-40 minute, every time 1~3h, suction filtration, merging filtrate；Filtrate is adsorbed with macroporous resin column, is then washed with deionized water to efflux is colourless and is eluted again with 30%~70% ethanol solution；Merge the eluent after macroporous resin purification, be concentrated into the 1/10 of original volume, reclaim ethanol, adjust solution ph to be 3 with hydrochloric acid and 5%NAOH, with ethyl acetate extraction 3~4 times, collect extract, concentrated with rotary evaporator, evaporated in vacuo obtains Echinacea Purpurea Herb P.E powder at 55 DEG C~65 DEG C.
2. Echinacea Purpurea Herb P.E preparation method according to claim 1, it is characterised in that the consumption of ethanol is 10~15 times of Echinacea weight, 1.5h~2h is extracted in refluxing extraction 2~3 times at 40~60 DEG C every time.
3. Echinacea Purpurea Herb P.E preparation method according to claim 1, it is characterised in that macroreticular resin model can select AB-8, S-8, H103, NKA-9, X-5, D4020, D3520, NKA-2, D4006 etc..
4. Echinacea Purpurea Herb P.E preparation method according to claim 1, it is characterised in that ethanol elution concentration is 30%~50% after macroporous resin adsorption.
5. Echinacea Purpurea Herb P.E according to claim 1, it is characterised in that the Echinacea medicinal material refers to pale reddish brown Echinacea Echinaceapurea (L.) Moench. stem, leaf, flower.
6. purposes of the Echinacea Purpurea Herb P.E in the medicine for preventing and treating senile dementia, health products are prepared as described in claim 1 to 5.
7. according to claim 6, it is characterised in that：The senile dementia is Alzheimer disease, vascular dementia, Alzheimer disease and vascular dementia and the Mixed dementia deposited is one or more of.
8. according to claim 7, it is characterised in that：The senile dementia is mainly Alzheimer disease.
9. the medicine of senile dementia or the preparation method of health products are prevented and treated according to claim 1 to 8, it is characterised in that：Its formulation is pill, granule, tablet, syrup, mixture, capsule, tincture, medicinal tea, injection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610190175.2A CN107281244A (en) | 2016-03-30 | 2016-03-30 | Echinacea Purpurea Herb P.E is preparing the application in preventing and treating senile dementia medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610190175.2A CN107281244A (en) | 2016-03-30 | 2016-03-30 | Echinacea Purpurea Herb P.E is preparing the application in preventing and treating senile dementia medicine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107281244A true CN107281244A (en) | 2017-10-24 |
Family
ID=60087625
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610190175.2A Pending CN107281244A (en) | 2016-03-30 | 2016-03-30 | Echinacea Purpurea Herb P.E is preparing the application in preventing and treating senile dementia medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107281244A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101292971A (en) * | 2008-06-25 | 2008-10-29 | 通化华夏药业有限责任公司 | Use of chicoric acid in preparing medicaments for treating dementia diseases |
-
2016
- 2016-03-30 CN CN201610190175.2A patent/CN107281244A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101292971A (en) * | 2008-06-25 | 2008-10-29 | 通化华夏药业有限责任公司 | Use of chicoric acid in preparing medicaments for treating dementia diseases |
Non-Patent Citations (1)
| Title |
|---|
| 吴启林等: "紫锥菊中菊苣酸提取纯化工艺研究", 《中草药》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Abenavoli et al. | Milk thistle in liver diseases: past, present, future | |
| Su et al. | The treatment of Alzheimer's disease using Chinese medicinal plants: from disease models to potential clinical applications | |
| ES2894362T3 (en) | A process to enhance the bioactivity of ashwagandha extracts | |
| US7824714B2 (en) | Chinese herb extract for treating dementia and preparation method thereof | |
| JP2009534321A (en) | Herbal medicine compositions and methods for their preparation and use | |
| JP2018524364A (en) | Compositions, methods and pharmaceutical compositions for liver treatment and liver health maintenance | |
| JP7490557B2 (en) | Compositions containing berberine | |
| CN105920476B (en) | Traditional Chinese medicine composition for preventing and treating Alzheimer disease and preparation method thereof | |
| RU2668135C1 (en) | Pharmaceutical composition for the treatment and prevention of degenerative neurological disorders which comprises, as an active ingredient, a mixed root extract of the tree peony root, the root of dahuric angelica and the root of thorowax or its fraction | |
| CN100512830C (en) | Pharmaceutical composition for treating senile dementia | |
| JP5654991B2 (en) | Combination of various plant extracts to improve symptoms of dementia disease | |
| US20220226413A1 (en) | Traditional chinese medicine composition with improving cognition effect, preparation method thereof and traditional chinese medicine preparation | |
| Liang et al. | Carthamus tinctorius L.: a natural neuroprotective source for anti-Alzheimer's disease drugs | |
| WO2008145064A1 (en) | The method for a sequoyitol-containing extract obtaining from the genus of trifolium, sobyean and ginkgo biloba and use thereof | |
| WO2012175018A1 (en) | Traditional chinese medicine composition for promoting nerve regeneration and preparation method and use thereof | |
| CN104027428B (en) | Preparation method of traditional Chinese medicine compound and application of traditional Chinese medicine compound in prevention and treatment of senile dementia | |
| CN105726622A (en) | Anti-fatigue traditional Chinese medicine combined extract and its preparation method and use | |
| CN107693530A (en) | Aurantiamarin and/or aurantiin are preparing the application in improving cognition dysfunction medicine | |
| CN102949535A (en) | Chinese herbal preparation resistant to hyperlipidemia and atherosclerosis and preparation method of Chinese herbal preparation | |
| RU2408384C2 (en) | Chinese medicinal composition, method for preparing and administration | |
| JP2001322935A (en) | Neurocyte activation agent and its use | |
| WO2022135329A1 (en) | Pharmaceutical composition containing erigerontis herba, ginseng radix et rhizoma, ophiopogonis radix and schisandrae chinensis fructus | |
| WO2009062374A1 (en) | The pharmaceutical use of liquiritigenin for preparing medicine for treating neurodegenerative diseases | |
| CN107281244A (en) | Echinacea Purpurea Herb P.E is preparing the application in preventing and treating senile dementia medicine | |
| CN111053819A (en) | Traditional Chinese medicine composition extract and application thereof in preparation of protein expression regulator |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20171024 |